Iterum Therapeutics plc (ITRMF) Total Non-Current Liabilities (2017 - 2024)

Iterum Therapeutics has reported Total Non-Current Liabilities for 8 years, with the latest figure at $48.7 million in Q4 2024.

• On a quarterly basis, Total Non-Current Liabilities rose 49.89% year-over-year to $48.7 million in Q4 2024; TTM through Dec 2024 was $48.7 million, a 49.89% increase from a year earlier, with the FY2024 full-year figure at $48.7 million, up 49.89% from the prior year.
• Total Non-Current Liabilities was $48.7 million for Q4 2024 at Iterum Therapeutics, up from $25.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $78.7 million in Q1 2021, with the low at $25.1 million in Q2 2024.
• Average Total Non-Current Liabilities over 5 years is $47.6 million, with a median of $37.9 million recorded in 2023.
• The sharpest annual moves came in 2020 and 2022: Total Non-Current Liabilities soared 211.83% in 2020, then slumped 59.1% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $77.5 million in 2020, then tumbled by 51.21% to $37.8 million in 2021, then fell by 0.82% to $37.5 million in 2022, then declined by 13.47% to $32.5 million in 2023, then surged by 49.89% to $48.7 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $48.7 million (Q4 2024), $25.1 million (Q2 2024), and $25.7 million (Q1 2024), per Business Quant data.